--- title: 'Accounts Payable Coordinator at REGENXBIO' canonical: 'https://feeny.ai/job/accounts-payable-coordinator-regenxbio-maryland-m7bjbn7g5wje' type: 'job' last_seen: '2026-11-09' --- # Accounts Payable Coordinator at REGENXBIO - **Company:** REGENXBIO - **Location:** Maryland - **Employment:** full-time - **Work type:** hybrid - **Posted:** 2026-11-05 - **Last confirmed live:** 2026-11-09 - **Apply:** https://jobs.lever.co/regenxbio/062b1081-a141-4500-944b-5206207e55bf ## Job description Since our founding in 2009, REGENXBIO has pioneered what’s possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients. Our work is fueled by purpose and urgency because every day matters to patients and their families. At REGENXBIO, you’ll find meaningful opportunities to grow, collaborate, and contribute to the advancement of potentially transformative gene therapies. Together, our talented team is working to make a meaningful difference for patients and their families. What we do matters. The Opportunity Reporting directly to the Sr. Manager, Accounts Payable, the Accounts Coordinator will be responsible for carrying out day-to-day accounts payable (AP) and other accounting-related activities. Primary activities involve the processing of accounts payable, interacting with suppliers and stakeholders to resolve outstanding issues, as well as other related activities within a high-volume, SOX compliant internal control environment.  Additionally, the position will help support the financial close process and interact directly with auditors on a quarterly basis to help facilitate the audit/review of annual and quarterly SEC filings. ## How You’ll Contribute - Processing AP, including the management of inbound invoices through the AP email system, processing invoices, and ensuring accuracy of coding for PO and Non-PO invoices. - Supplier Statement Reconciliations - Assist in monthly close process - Interact cross-functionally with stakeholders in various departments to resolve discrepancies - Manage Supplier relationships and payment inquiries - Ensure compliance with internal controls and company policies - Acquire expert knowledge in accounting systems and continuously assess processes for improvements - Participate in external audits and provide support as necessary - Perform special projects and other tasks as needed by the Accounting Department - It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships, and using clear communication to meet shared objectives. ## What You’ll Bring We are looking for someone who thrives in a collaborative, patient-focused environment with the following skills: - Bachelor’s Degree - accounting preferred - Minimum of 2 years experience in progressive AP or similar roles - Public company, biotech/pharma experience preferred - Extensive experience with and understanding of the AP process - Understanding of accrual-based accounting concepts - Experience working with ERP systems (Oracle Fusion preferred) - Experience with expense report processing - Experience in performing monthly financial close procedures, including journal entries and balance sheet reconciliations - Excellent organizational, analytical, interpersonal and communication skills - Ability to work independently and with a team in a fast-paced and high-volume environment - Ability to budget and manage time appropriately - Advanced proficiency in Excel ## What You Can Expect At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values - trust, accountability, perseverance, and innovation - drive everything we do. We offer a comprehensive and competitive benefit and compensation package that includes market-competitive salaries, an annual bonus program, education assistance, paid caregiver leave, a retirement plan with employer match, stock options at all levels, summer hours, and more. The estimated compensation range for this role is $70,000 – $90,000 annually. The actual salary offered to the final candidate depends on factors such as relevant work experience, skills, education, and years of experience. ## About REGENXBIO ## Company Overview - **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform. - **Entity Type**: Public (NASDAQ: RGNX) - **Headquarters**: Rockville, Maryland, United States - **Founded**: 2008 (founded as a company; operations began in 2009) - **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university. ## Core Business - **Primary industry**: Biotechnology – Gene Therapy (AAV-based) - **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy). - **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Products & Services - **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®). - **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials. - **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development. - **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development. - **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022. ## Market Standing - **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx) - **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx) - **Notable Investors/Partners**: - AbbVie (collaboration for ABBV-RGX-314) - Nippon Shinyaku (partnerships for RGX-121 and RGX-111) - Novartis (licensee for ZOLGENSMA® using NAV vectors) - **Growth Signals**: - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx) - BLA submission for RGX-202 targeted for 2026. - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing. - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx) ## Competitive Advantages - **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing. - **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®). - **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways. ## Strategic Focus - **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy. - **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku. - **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies. ## Why Work Here - **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases. - **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization. - **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site. - **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles). - **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams. - **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Sources 1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/) 2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx) 3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) 4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview) 5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio) ## Other roles at REGENXBIO - [Market Development Director - Northeast Region](https://feeny.ai/job/market-development-director-northeast-region-regenxbio-northeast-united-states-p1aq4vpnf89y) — Northeast United States - [Market Development Director - Central Region](https://feeny.ai/job/market-development-director-central-region-regenxbio-central-united-states-15nj813awggq) — Central United States - [Market Development Director - West Region](https://feeny.ai/job/market-development-director-west-region-regenxbio-west-coast-1j7btq7v405v) — West Coast - [Senior Director, Payer Accounts](https://feeny.ai/job/senior-director-payer-accounts-regenxbio-remote-s2pgqn6da73z) - [Lead Integration Developer](https://feeny.ai/job/lead-integration-developer-regenxbio-rockville-x52a6y2n5b0w) — Rockville, MD - [VP, Global Rare Disease Franchise](https://feeny.ai/job/vp-global-rare-disease-franchise-regenxbio-remote-zw2996mdrwy4) - [Vice President, Information Technology](https://feeny.ai/job/vice-president-information-technology-regenxbio-rockville-ekqdx4dtve6s) — Rockville, MD - [People Intern](https://feeny.ai/job/people-intern-regenxbio-rockville-mq2tm3vcjxe7) — Rockville, MD - [Associate Director, Regulatory Affairs](https://feeny.ai/job/associate-director-regulatory-affairs-regenxbio-rockville-1grfyr3vz4sy) — Rockville, MD - [Head of Sales, Rare Disease](https://feeny.ai/job/head-of-sales-rare-disease-regenxbio-remote-qhp7fgpvfvzm)